Dana-Farber to Present Phase 3 Lung Cancer Data at ESMO
Dana-Farber will present the phase 3 DeLLphi-305 primary analysis in extensive-stage small cell lung cancer at the 2026 ESMO Presidential ...
Tag: tarlatamab
Hidden Immune Cells Offer New Hope Against the Deadliest Lung Cancer
WEHI researchers have discovered that gamma delta T cells can recognise and kill small cell lung cancer, and that two ...
Single-Cell Atlas Reveals DLL3 as a Drug Target in Aggressive Cervical Cancer
A single-cell multi-omic atlas of neuroendocrine carcinoma of the cervix identifies DLL3 as a driver of immune evasion and validates ...
Subcutaneous Tarlatamab Shows Safety and Early Activity in Small Cell Lung Cancer
A phase 1b study presented at the IASLC 2026 World Conference on Lung Cancer found that subcutaneous tarlatamab was well ...
Longer Gaps Between Tarlatamab Doses Show Promise in Small Cell Lung Cancer
The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!